CytRx (CYTR) Announces Earnings Results

CytRx (NASDAQ:CYTR) announced its earnings results on Wednesday. The biotechnology company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01, Fidelity Earnings reports.

NASDAQ:CYTR traded up $0.03 during trading hours on Thursday, reaching $0.55. 4,594 shares of the company traded hands, compared to its average volume of 149,767. The stock has a market cap of $17.50 million, a PE ratio of -1.92 and a beta of 2.13. CytRx has a 1-year low of $0.33 and a 1-year high of $1.38.

Separately, HC Wainwright set a $5.00 target price on CytRx and gave the company a “buy” rating in a report on Tuesday, February 5th.

TRADEMARK VIOLATION NOTICE: “CytRx (CYTR) Announces Earnings Results” was published by Stock Observer and is the property of of Stock Observer. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.thestockobserver.com/2019/05/16/cytrx-cytr-announces-earnings-results.html.

About CytRx

CytRx Corporation, a biopharmaceutical company, engages in the research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. The company is developing its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR (linker activated drug release) technology platform, a discovery engine designed to leverage its expertise in albumin biology and linker technology for the development of anti-cancer therapies.

See Also: Bear Market – How and Why They Occur

Earnings History for CytRx (NASDAQ:CYTR)

Receive News & Ratings for CytRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx and related companies with MarketBeat.com's FREE daily email newsletter.